SCHEMBL3019523

SCHEMBL3019523

CCOc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MAPT P10636 2/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
GAA P10253 2/20 0.51
PKM P14618 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51
TP53 P04637 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
KMT2A Q03164 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014207 0.91 LMNA (0.54) L3MBTL1SMN1; SMN2GAAPKMNPSR1
SCHEMBL3009160 0.91 GAA (0.51) ALDH1A1L3MBTL1SMN1; SMN2MAPTGAA
SCHEMBL3006461 0.91 MEN1 (0.49) ALDH1A1L3MBTL1SMN1; SMN2MAPTUSP2
SCHEMBL3009005 0.91 TDP1 (0.60) ALDH1A1L3MBTL1SMN1; SMN2MAPTGAA
SCHEMBL3007698 0.90 MAPT (0.61) ALDH1A1L3MBTL1SMN1; SMN2MAPTUSP2
SCHEMBL3017548 0.90 HDAC3 (0.49) ALDH1A1L3MBTL1SMN1; SMN2MAPTUSP2
SCHEMBL3023130 0.89 ALDH1A1 (0.60) ALDH1A1L3MBTL1SMN1; SMN2MAPTUSP2
SCHEMBL3007892 0.89 MAPT (0.47) ALDH1A1L3MBTL1SMN1; SMN2MAPTUSP2
SCHEMBL3021000 0.89 MEN1 (0.48) L3MBTL1SMN1; SMN2GAAPKMNPSR1
SCHEMBL3001249 0.88 TDP1 (0.48) ALDH1A1L3MBTL1SMN1; SMN2MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885L3MBTL1 1847/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.